G320(P) Adenosine deaminase 2 deficiency with a novel variant of CECR1 gene mutation: responding to tumor necrosis factor antagonist therapy

Antagonist Therapy ◽

Novel Variant ◽

Adenosine Deaminase 2 ◽

Factor Antagonist ◽

Adenosine deaminase 2 deficiency with a novel variant of CECR1 gene mutation: Responding to tumor necrosis factor antagonist therapy

Indian Journal of Rheumatology ◽

10.4103/injr.injr_36_19 ◽

2019 ◽

Vol 14 (3) ◽

pp. 236

Author(s):

ZakiyaSaleh Al Mosawi ◽

HibaOmar Abduljawad ◽

MaryamYusuf Busehail ◽

BarrakMahmood Al Moosawi

Keyword(s):

Tumor Necrosis Factor ◽

Adenosine Deaminase ◽

Gene Mutation ◽

Tumor Necrosis ◽

Antagonist Therapy ◽

Novel Variant ◽

Adenosine Deaminase 2 ◽

Factor Antagonist ◽

Refractory Lymphocytic Enterocolitis and Tumor Necrosis Factor Antagonist Therapy

Clinical Gastroenterology and Hepatology ◽

10.1016/j.cgh.2009.12.010 ◽

2010 ◽

Vol 8 (4) ◽

pp. 391-394 ◽

Cited By ~ 7

Author(s):

Ghazaleh Aram ◽

Theodore M. Bayless ◽

Zong–Ming Chen ◽

Elizabeth A. Montgomery ◽

Mark Donowitz ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Antagonist Therapy ◽

Factor Antagonist ◽

National Practice Patterns in Tuberculosis and Hepatitis Screening Prior to Tumor Necrosis Factor Antagonist Therapy in Veterans with Inflammatory Bowel Disease

The American Journal of Gastroenterology ◽

10.14309/00000434-201310001-01789 ◽

2013 ◽

Vol 108 ◽

pp. S539

Author(s):

Jason Hou ◽

Jennifer Kramer ◽

Peter Richardson ◽

Shubhada Sansgiry ◽

Hashem El-Serag

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Practice Patterns ◽

Antagonist Therapy ◽

Inflammatory Bowel ◽

National Practice ◽

Factor Antagonist ◽

Sa1723 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Crohn's Disease: A Multicenter Consortium Propensity Score-Matched Analysis

Gastroenterology ◽

10.1016/s0016-5085(18)31547-6 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-369-S-370 ◽

Cited By ~ 1

Author(s):

Matthew Bohm ◽

Sashivar Sagi ◽

Monika Fischer ◽

Siri Kadire ◽

Gloria Tran ◽

...

Keyword(s):

Crohn’S Disease ◽

Tumor Necrosis Factor ◽

Crohn's Disease ◽

Propensity Score ◽

Comparative Effectiveness ◽

Tumor Necrosis ◽

Antagonist Therapy ◽

Factor Antagonist ◽

328 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Ulcerative Colitis: A Multicenter Consortium Propensity Score-Matched Analysis

Gastroenterology ◽

10.1016/s0016-5085(18)30723-6 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-82 ◽

Cited By ~ 1

Author(s):

David Faleck ◽

Preeti Shashi ◽

Joseph Meserve ◽

Mahmoud Rahal ◽

Siri Kadire ◽

...

Keyword(s):

Ulcerative Colitis ◽

Tumor Necrosis Factor ◽

Propensity Score ◽

Comparative Effectiveness ◽

Tumor Necrosis ◽

Antagonist Therapy ◽

Factor Antagonist ◽

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

Arthritis & Rheumatism ◽

10.1002/art.30373 ◽

2011 ◽

Vol 63 (7) ◽

pp. 1793-1803 ◽

Cited By ~ 87

Author(s):

M. C. Genovese ◽

N. Kinnman ◽

G. de La Bourdonnaye ◽

C. Pena Rossi ◽

P. P. Tak

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Phase Ii ◽

Tumor Necrosis ◽

Dose Finding ◽

Inadequate Response ◽

Antagonist Therapy ◽

Factor Antagonist ◽

277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis

Gastroenterology ◽

10.1016/s0016-5085(18)30684-x ◽

2018 ◽

Vol 154 (6) ◽

pp. S-68 ◽

Cited By ~ 3

Author(s):

Dana J. Lukin ◽

Aaron Weiss ◽

Satimai Aniwan ◽

Siri Kadire ◽

Gloria Tran ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Propensity Score ◽

Tumor Necrosis ◽

Antagonist Therapy ◽

Inflammatory Bowel ◽

Comparative Safety ◽

Factor Antagonist ◽

284 Tuberculosis and Hepatitis B Reactivation Are Rare After Treatment With Tumor Necrosis Factor Antagonist Therapy Among Patients With Inflammatory Bowel Disease

Gastroenterology ◽

10.1016/s0016-5085(15)30213-4 ◽

2015 ◽

Vol 148 (4) ◽

pp. S-61

Author(s):

Jason K. Hou ◽

Jennifer R. Kramer ◽

Peter Richardson ◽

Shubhada Sansgiry ◽

Hashem B. El-Serag

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Hepatitis B ◽

Bowel Disease ◽

Tumor Necrosis ◽

Antagonist Therapy ◽

Inflammatory Bowel ◽

Factor Antagonist ◽

Reliability of Tuberculosis Screening Test in Patients Receiving Tumor Necrosis Factor Antagonist Therapy in a United States Rheumatology Clinic

10.21236/ada577631 ◽

2013 ◽

Author(s):

Himabindu Borra ◽

Daniel F. Battafarano ◽

Ramon Arroyo ◽

Michael J. Morris ◽

Michelle Sit ◽

...

Keyword(s):

United States ◽

Tumor Necrosis Factor ◽

Screening Test ◽

Tumor Necrosis ◽

Tuberculosis Screening ◽

Antagonist Therapy ◽

Rheumatology Clinic ◽

Factor Antagonist ◽

Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis

Seminars in Arthritis and Rheumatism ◽

10.1016/j.semarthrit.2010.04.003 ◽

2010 ◽

Vol 40 (3) ◽

pp. 233-240 ◽

Cited By ~ 157

Author(s):

Angelique N. Collamer ◽

Daniel F. Battafarano

Keyword(s):

Tumor Necrosis Factor ◽

Clinical Features ◽

Tumor Necrosis ◽

Skin Lesions ◽

Psoriatic Skin ◽

Antagonist Therapy ◽

Factor Antagonist ◽